The need to identify biomarkers for bevacizumab-based treatment in advanced colorectal
cancer is imperative. The aim of this study was to investigate the prognostic role of …

Simple Summary Molecular biology knowledge has enabled the incorporation of targeted
therapies, such as the anti-angiogenic drug bevacizumab, into combined chemotherapy …

Novel predictive biomarkers are needed to improve patient selection and optimize the use of
bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating …

This study intends to identify biomarkers that could refine the selection of patients with
metastatic colorectal cancer (mCRC) for bevacizumab treatment. Pretreatment 36 plasma …

Background: To identify whether circulating levels of angiogenesis-related factors may be
predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) …

480 Background: Bevacizumab (BV) plus chemotherapy (chemo) has been shown to
improve survival for metastatic colorectal cancer (mCRC). Stromal cell-derived factor-1 (SDF …

Background Bevacizumab improves progression free survival (PFS) and overall survival
(OS) in metastatic colorectal cancer patients however currently there are no biomarkers that …

Bevacizumab is the first anti-angiogenic agent approved for the treatment of metastatic
colorectal cancer. The need for patient selection before initiating therapy necessitates the …

Despite treatment of patients with metastatic colorectal cancer (mCRC) with bevacizumab
plus chemotherapy, response rates are modest and there are no biomarkers available that …

Background Bevacizumab has shown consistent clinical efficacy in metastatic colorectal
cancer (mCRC), but some patients respond better than others. Thus, it is crucial to identify …